Clinical Trials Browser

Phase 2 × INDUSTRY × vitespin × Clear all

NCT01147536 2021-06-03

Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

Phase 2 Terminated

12 enrolled 5 charts

Carcinoma, Renal Cell

NCT00098085 2009-03-09

Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms